Welcome to our dedicated page for Wellgistics Health SEC filings (Ticker: WGRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Wellgistics Health, Inc. (NASDAQ: WGRX) SEC filings page on Stock Titan brings together the company’s official disclosures to U.S. regulators, including current reports on Form 8-K, quarterly reports on Form 10-Q, and related exhibits. These documents provide detail on Wellgistics Health’s operations as a pharmacy physical and technology enabling health IT company that connects more than 6,500 pharmacies and over 200 manufacturers through wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services.
Through its filings, Wellgistics has reported material events such as the license agreement with DataVault AI Inc. for intellectual property used to develop its PharmacyChain™ manufacturer-to-patient blockchain-enabled smart contracts platform, sponsorship and licensing arrangements related to Dream Bowl 2026, and debt conversion agreements. Filings also describe the launch and positioning of the EinsteinRx™ pharmacy dispensing optimization AI platform, changes in independent registered public accounting firms, and the reporting of quarterly financial results.
Investors can also review an 8-K describing a Nasdaq notice regarding the company’s minimum bid price deficiency and the associated compliance period, which outlines potential implications for the continued listing of WGRX on The Nasdaq Capital Market. These regulatory documents offer insight into governance, capital structure, strategic partnerships, and risk factors referenced in the company’s public communications.
On Stock Titan, SEC filings for WGRX are supplemented with AI-powered summaries that highlight key terms, financial metrics, and business developments from lengthy documents. Users can quickly identify items related to licensing arrangements, sponsorship agreements, auditor changes, and listing compliance, while still having access to the full text as filed with the SEC. The page also provides convenient access to forms associated with insider and shareholder-related activity when available, helping users track how Wellgistics Health’s regulatory profile evolves over time.
Wellgistics Health, Inc. released a shareholder letter outlining a major strategic shift toward vertically integrated, blockchain-based healthcare infrastructure. Management explains how recent transactions are meant to connect data, verification, and patient engagement across its EinsteinRx™ AI platform and PharmacyChain™ smart-contract system.
The Company highlights formation of DelivMeds AI and an expanded Datavault license to support tokenized healthcare data, acquisition plans for the QOLPOM patent portfolio to add biometric verification and medical drone capabilities, and a controlling interest in Tollo Health with its Forzet™ offering. Through the Health Lives Here program with NFL Alumni Health, Wellgistics aims to gather real-world GLP-1 patient data that feeds back into its platform.
Wellgistics notes it already connects more than 6,500 pharmacies and 200+ manufacturers and views the pharmacy as a key data and adherence touchpoint. The letter also references a planned share restructuring and new CUSIP and includes extensive forward‑looking statements about revenue expectations, app launch timing, platform integration, and regulatory and execution risks.
Wellgistics Health, Inc. released a shareholder letter outlining a major strategic shift toward vertically integrated, blockchain-based healthcare infrastructure. Management explains how recent transactions are meant to connect data, verification, and patient engagement across its EinsteinRx™ AI platform and PharmacyChain™ smart-contract system.
The Company highlights formation of DelivMeds AI and an expanded Datavault license to support tokenized healthcare data, acquisition plans for the QOLPOM patent portfolio to add biometric verification and medical drone capabilities, and a controlling interest in Tollo Health with its Forzet™ offering. Through the Health Lives Here program with NFL Alumni Health, Wellgistics aims to gather real-world GLP-1 patient data that feeds back into its platform.
Wellgistics notes it already connects more than 6,500 pharmacies and 200+ manufacturers and views the pharmacy as a key data and adherence touchpoint. The letter also references a planned share restructuring and new CUSIP and includes extensive forward‑looking statements about revenue expectations, app launch timing, platform integration, and regulatory and execution risks.
Wellgistics Health, Inc. entered into a fully binding letter of intent with Datavault AI, EOS, Scilex, HealthBridge Advisors and Fortitude Advisors for a multi‑step transaction that would contribute healthcare data, drone logistics and consumer health assets into the company. The parties target an approximate combined asset value of $4.0 billion, subject to an independent fairness opinion and numerous approvals and financing conditions.
The structure would use new preferred stock convertible into common shares so that these counterparties are expected to own about 89.6% of the common stock after conversion, with existing public stockholders retaining about 10.4%, subject to adjustment. Wellgistics also amended a note purchase agreement, increasing the investor’s cash funding to $1.2 million and the related note’s principal to $1.5 million. Separately, the board and stockholders approved a 1‑for‑50 reverse stock split, reducing outstanding shares from roughly 125.7 million to about 2.5 million to help regain Nasdaq minimum bid‑price compliance.
Wellgistics Health, Inc. entered into a fully binding letter of intent with Datavault AI, EOS, Scilex, HealthBridge Advisors and Fortitude Advisors for a multi‑step transaction that would contribute healthcare data, drone logistics and consumer health assets into the company. The parties target an approximate combined asset value of $4.0 billion, subject to an independent fairness opinion and numerous approvals and financing conditions.
The structure would use new preferred stock convertible into common shares so that these counterparties are expected to own about 89.6% of the common stock after conversion, with existing public stockholders retaining about 10.4%, subject to adjustment. Wellgistics also amended a note purchase agreement, increasing the investor’s cash funding to $1.2 million and the related note’s principal to $1.5 million. Separately, the board and stockholders approved a 1‑for‑50 reverse stock split, reducing outstanding shares from roughly 125.7 million to about 2.5 million to help regain Nasdaq minimum bid‑price compliance.
Wellgistics Health, Inc. reported first quarter 2026 results showing rapid revenue growth and a much smaller loss. Wellgistics Pharmacy monthly revenue increased from approximately $0.1 million in November 2025 to approximately $0.6 million in April 2026, based on preliminary unaudited results.
Company revenue was $0.486 million in Q4 2025 and $0.929 million in Q1 2026, and the Company expects revenue of $1.775 million in Q2 2026. Net operating loss narrowed to $7.742 million in the quarter ended March 30, 2026 from $32.430 million a year earlier, with loss per share improving to $0.07 from $0.62.
Management highlighted cost reductions, a Kare Pharmtech joint venture providing access to over 200,000 patient lives, an expanded partnership with Tollo Health, added capabilities such as insurance eligibility verification, and a growing focus on GLP-1 related opportunities and PharmacyChain™/EinsteinRx™ integration.
Wellgistics Health, Inc. reported very weak first-quarter 2026 results, highlighting serious financial strain and Nasdaq listing risks. Net revenues fell to $1.56 million from $10.86 million a year earlier, reflecting a sharp drop in distribution product revenue partly offset by higher pharmacy and logistics sales.
The company posted a net loss of $7.74 million, though this was smaller than the prior-year loss of $32.43 million, and generated a gross profit of only $170,221. Operating expenses were $6.19 million, and net interest expense remained heavy.
As of March 31, 2026, Wellgistics held just $51,730 of cash against $45.19 million of liabilities and a stockholders’ deficit of $15.06 million, prompting management and auditors to state that there is substantial doubt about its ability to continue as a going concern.
During the quarter the company raised $6.5 million of cash through secured convertible notes with an $8.13 million face amount and issued significant equity and warrants to settle compensation and vendor obligations, further diluting shareholders.
Wellgistics also received Nasdaq deficiency notices for failing the $1.00 minimum bid price and the $2.5 million minimum stockholders’ equity requirements. Management is pursuing additional financing, a potential reverse stock split, a new collaboration venture, and proxy proposals to adjust its capital structure, but outcomes remain uncertain.
Wellgistics Health, Inc. filed an 8-K to state that it will report financial results for the first quarter of 2026 on Tuesday, May 19, 2026 after the market closes. The information is furnished under Regulation FD, meaning it is provided for disclosure purposes and not deemed filed under securities laws.
The company describes itself as a health information technology and pharmaceutical distribution business that integrates its EinsteinRx AI pharmacy optimization platform with its blockchain-enabled PharmacyChain smart contracts platform. This network links more than 6,500 pharmacies and over 200 manufacturers to support distribution, prescription routing, direct-to-patient delivery, and AI-powered hub services.
The accompanying press release also includes forward-looking statements about a proposed acquisition of WellCare Today, LLC and potential integration of remote monitoring and care-coordination technologies, while highlighting numerous regulatory, financing, operational, and reimbursement risks that could cause actual outcomes to differ.
Wellgistics Health, Inc. reported that it has requested withdrawal of its Preliminary Proxy Statement on Schedule 14A related to a planned special meeting of stockholders. The company decided not to move forward with those preliminary proxy materials as it continues to evaluate potential strategic transactions.
Wellgistics noted that it may file revised proxy materials at a later date once its review progresses. No definitive proxy materials connected to the withdrawn preliminary proxy statement were mailed or otherwise distributed to stockholders.
Wellgistics Health, Inc. is amending and restating its prior proxy to convert a scheduled special meeting into its 2026 annual meeting to be held virtually on June 19, 2026 and to present multiple governance and capital-structure proposals for stockholder approval.
The proposals include a name change to Vantix Health Inc., authorization of 10,000,000 shares of blank-check preferred stock, an amendment to the Equity Incentive Plan to add 56,493,936 shares and reserve an additional 100,000 super-voting preferred shares, approval to designate and issue a one-for-one convertible preferred series, approval to issue a new super-voting preferred series to certain directors and officers, and approval under Nasdaq rules to permit future issuances that could exceed 19.99% of outstanding common stock under certain circumstances. The record date for voting is April 22, 2026, with 126,653,372 shares outstanding as of that date.
Wellgistics Health, Inc., through its subsidiary Wellgistics, LLC, entered into an Acknowledgment of Indebtedness, Forbearance and Repayment Agreement with Marco Capital, Inc. on May 1, 2026. Wellgistics acknowledged approximately $1.77 million in outstanding obligations under a prior Loan and Security Agreement.
Under the Forbearance Agreement, Marco Capital agreed to temporarily forbear from exercising certain rights and remedies through June 15, 2026. Wellgistics must make bi-weekly payments of $50,000 starting May 5, 2026, and a portion of net proceeds from future financings during the forbearance period may need to be applied to repayment. The obligations will accrue interest at a rate equal to Term SOFR plus 11.5% per annum beginning May 5, 2026.